02/11/16 - 12:00 PM EST
With new stock option grants this week, Epizyme executives are sending an ugly message to aggrieved shareholders: We don't mind profiting from your pain.
02/11/16 - 09:32 AM EST
Incyte is halting all clinical trials intended to expand the use of its blood cancer drug Jakafi into solid tumors due to an insufficient level of efficacy.
02/10/16 - 08:28 AM EST
In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.
02/09/16 - 10:00 AM EST
Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.
02/04/16 - 08:43 AM EST
Someone needs to send MannKind executives a primer on the uses of Twitter hashtags.
02/03/16 - 06:00 AM EST
Foster City, Calif.-based biotech giant Gilead announced a new $12 billion share repurchase plan on Tuesday night in conjunction with fourth-quarter earnings.
02/02/16 - 10:17 AM EST
The disclosure that Pfizer shelved an Alzheimer's drug because of disappointing efficacy is driving down the market value of Axovant Sciences, which is developing a similar drug.
02/01/16 - 08:02 AM EST
Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.
02/01/16 - 06:08 AM EST
Biotech news and observations to start the week.
01/29/16 - 08:16 AM EST
The list price for Merck's newly approved hepatitis C drug is lower than competing therapies from Gilead Sciences and Abbvie, which means a new price war could be heating up.